SPECC1 and COVID-19: For instance, Nirmatrelvir, a main protease inhibitor (Nsp5) found in Paxlovid, has been approved for treating high-risk COVID-19 patients [16], though resistance to this drug has been reported shortly after its introduction [17,18].